EGFR and cancer: The ETAR antagonists ZD4054 and atrasentan used combined with the EGFR inhibitor gefitinib and the monoclonal HER2-specific antibody trastuzumab, respectively, present a powerful capacity to repress the proliferation and invasion of cancer cells.